CCR5 and neoplasm: Overall, these reports suggest that this nexus of tumor cells that express CCR5 and stroma cell-derived CC class chemokine ligands provide breast cancer investigators a new set of novel therapeutic targets (7, 12, 13, 16, 18, 19).